Zai Lab Announces Launch of Optune® in Hong Kong for Patients with Glioblastoma Multiforme - TC Read more about Zai Lab Announces Launch of Optune® in Hong Kong for Patients with Glioblastoma Multiforme - TC
Zai Lab to Present at the 37th Annual J.P. Morgan Healthcare Conference - TC Read more about Zai Lab to Present at the 37th Annual J.P. Morgan Healthcare Conference - TC
Zai Lab Announces Acceptance of NDA Submission of ZEJULA (Niraparib) in Mainland China by the NMPA - TC Read more about Zai Lab Announces Acceptance of NDA Submission of ZEJULA (Niraparib) in Mainland China by the NMPA - TC
MacroGenics and Zai Lab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Margetuximab, MGD013 and TRIDENT™ Molecule in Greater China - TC Read more about MacroGenics and Zai Lab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Margetuximab, MGD013 and TRIDENT™ Molecule in Greater China - TC
Zai Lab and Novocure Awarded Deal of the Year - TC Read more about Zai Lab and Novocure Awarded Deal of the Year - TC
Zai Lab Limited Announces Presentations at November Conferences - TC Read more about Zai Lab Limited Announces Presentations at November Conferences - TC
Zai Lab Announces Approval of ZEJULA® (Niraparib) for Patients with Relapsed Ovarian Cancer in Hong Kong - TC Read more about Zai Lab Announces Approval of ZEJULA® (Niraparib) for Patients with Relapsed Ovarian Cancer in Hong Kong - TC
Five Prime Therapeutics and Zai Lab Dosed First Patient in Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers - TC Read more about Five Prime Therapeutics and Zai Lab Dosed First Patient in Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers - TC
Zai Lab Appoints Industry Leader Tao Fu as President & Chief Operating Officer, Expands US Presence - TC Read more about Zai Lab Appoints Industry Leader Tao Fu as President & Chief Operating Officer, Expands US Presence - TC
Zai Lab Presents Interim Results of its ongoing Phase 2 study of ZL-2301 (brivanib) in Chinese Patients with Advanced Hepatocellular Carcinoma (HCC) at the 21st Annual Meeting of the Chinese Society of Clinical Oncology - TC Read more about Zai Lab Presents Interim Results of its ongoing Phase 2 study of ZL-2301 (brivanib) in Chinese Patients with Advanced Hepatocellular Carcinoma (HCC) at the 21st Annual Meeting of the Chinese Society of Clinical Oncology - TC